An experimental injectable not yet submitted to the US Food and Drug Administration has become a target for online vendors, med spas, and compounding pharmacies.
Eli Lilly’s triple‑agonist retatrutide is part of a new generation of obesity medicines drawing intense public interest. Early trial results showing weight loss of